Navigation Links
400 Series/Soft Tube Esophageal Stethoscope

Products400 Series/Soft Tube Esophageal Stethoscope
Company DeRoyal
Item 400 Series/Soft Tube Esophageal Stethoscope
Features 
  • Provides 28% better auditory response (sensitivity) than leading competitor
  • Designed for use in surgical setting to monitor heart and respiratory sounds and to measure core body temperature anesthetized patients
  • Provides outstanding heart and respriatory sound transmission
  • Available with or without temperature monitoring capability
  • Complete line includes all popular French sizes
  • Fully compatible with most monitors
  • Available in extra-long lengths
  • Available in both regular and soft flexiblity for enhanced patient comfort
  • Atraumatic, low-friction surface for ease of insertion
  • Thin distal cuff allows optimal sound transmission and fidelity
  • Positive locking connector for secure cable connection
  • Latex safe
  • All packaged Sterile 25/Bx, 2Bxs/Cs
  • Description The pause of a heartbeat. The bodys warmth beneath drapes. The life-giving force of rhythmic breathing. These vital signs are yours to guard, measure, stabilize and cross check. DeRoyals line of Temperature Monitoring products helps you do your job, giving you the information needed to provide the most comfortable and precise management of your patients stability during surgical procedures. These products are designed to be as vigilant as you are, so you can confidently regulate healing.

    DeRoyal offers an extensive line of temperature monitoring products. For complete details, please see DeRoyals Temperature Monitoring Literature.
    Info DeRoyal
    Customer Service: (888) 938-7828
    Web site: http://www.deroyal.com

    Related medicine products :

    1. 700 Series/Soft Tube Esophageal Stethoscope
    2. Combitube® Esophageal/Tracheal Double-Lumen Airway
    3. 400 Series/Regular Tube Esophageal Stethoscope
    4. Esophageal Stethoscope
    5. 400 Series/Extra-Long Length Esophageal Stethoscope
    6. 700 Series/Regular Tube Esophageal Stethoscope
    7. 400 Series Esophageal Stethoscope
    8. Thermocouple Esophageal Stethoscope
    9. Regular Tube Esophageal Stethoscope Without Temperature Sensor
    10. 70S Series Esophageal Stethoscope
    11. 700 Series/Extra-Long Length Esophageal Stethoscope
    ... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
    ... hand-held, point-of-care device for the qualitative detection of ... The TOX/See device can detect up to nine ... to 8 minutes and requires only a few ... packaged to maximize convenience and ease of use. ...
    ... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
    ... is a 1-step, hand-held, point-of-care device for the ... human urine. The TOX/See device can detect ... drugs in 3 to 8 minutes and requires ... cassette is individually packaged to maximize convenience and ...
    Medicine Products:
    (Date:8/4/2015)... ... August 04, 2015 , ... ... examination now offered by the world renowned Beverly Hills facelift surgeon , ... through cosmetic surgery techniques helps individuals to achieve an outer appearance that meets ...
    (Date:8/4/2015)... Denver, CO (PRWEB) , ... August 04, 2015 ... ... for skilled nursing homes and other long-term care facilities, today announced details of ... (QAPI) for nursing homes and centers. , Providigm’s QAPI Accreditation program , ...
    (Date:8/4/2015)... (PRWEB) , ... August 04, ... ... its HealthCenter personal health record (PHR) product has achieved Office of the ... Inpatient EHR Certification from Drummond Group. HealthCenter delivers the highest quality personal ...
    (Date:8/4/2015)... ... ... METTLER TOLEDO has announced an upcoming online symposium entitled ... and Merck. This free online seminar will be held on September 24, ... decisions with limited process understanding. Established methods have been developed to facilitate ...
    (Date:8/4/2015)... ... ... The results of a three year clinical trial for the Argus II, a ... blindness, were published on June 23, 2015 in Ophthalmology , the journal of ... more commonly known as the “bionic eye,” is safe and effective for long-term treatment ...
    Breaking Medicine News(10 mins):Health News:Beverly Hills Surgeon, Dr. Paul Nassif, is Now Offering Personal Consultations with Full Examinations for Facial Plastic Surgeries 2Health News:Beverly Hills Surgeon, Dr. Paul Nassif, is Now Offering Personal Consultations with Full Examinations for Facial Plastic Surgeries 3Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 2Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 3Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 2Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 3Health News:METTLER TOLEDO Announces New Process Chemistry and Scale-up Online Seminar 2Health News:“Bionic Eye” Implant for the Blind Proved Safe and Effective at the End of a Three Year Clinical Trial 2
    ... National Government Services subsidiary Medicare ... York and Connecticut, INDIANAPOLIS, May 5 WellPoint, ... Inc.,subsidiary was selected by the Centers for Medicare & ... Jurisdiction 13,which includes the states of New York and ...
    ... kidney disease from high blood pressure did not keep ... of African-Americans studied, according to long-term results of a ... in the Archives of Internal Medicine. , The largest ... the African American Study of Kidney Disease and ...
    ... more with exclusive summer ... travel packages for 2008., SAN RAFAEL, ... Hotels & Restaurants Group announced today a,series of travel packages for ... KN Tranquility Suite(TM) offers opulent, comfort-inspired,surroundings in the heart of Chicago,s ...
    ... 5 ConforMIS, Inc., a privately,held company that ... treatment of osteoarthritis and joint damage, today,announced the ... Officer.,The addition fully rounds out the executive team, ... Chief Executive Officer and Phil Licari,as Chief Operating ...
    ... fewer brain bleeds than aspirin, study finds , , MONDAY, May ... good as aspirin at preventing recurrent stroke and it causes ... Peking University First Hospital in Beijing shows. , The trial ... to 18 months and 359 patients who took aspirin for ...
    ... prescriptions for $10, more women,s health offerings, and $4 ... BENTONVILLE, Ark., May 5 While health care,costs ... Stores, Inc.,(NYSE: WMT ) is furthering its efforts ... costs and providing ongoing savings,through its pharmacy offerings., ...
    Cached Medicine News:Health News:WellPoint Wins Medicare Administrative Contract Worth up to $323 Million 2Health News:Kidney disease worsens in a fourth of African-Americans despite therapy for hypertension 2Health News:KN Tranquility Suite(TM) Hosts Spa Indulgences and High-Tea Service on the Magnificent Mile 2Health News:KN Tranquility Suite(TM) Hosts Spa Indulgences and High-Tea Service on the Magnificent Mile 3Health News:ConforMIS Completes Executive Team With Addition of CFO 2Health News:Anti-Clotting Drug as Good as Aspirin at Stopping Second Stroke 2Health News:Wal-Mart Launches Phase Three of $4 Prescription Program 2Health News:Wal-Mart Launches Phase Three of $4 Prescription Program 3Health News:Wal-Mart Launches Phase Three of $4 Prescription Program 4
    (Date:8/4/2015)... 2015  Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) ... million for the three and six months ended June ... $12.1 million and $43.4 million for the same periods ... primarily by the more than $90 million of revenue ... upfront payment from Bayer to license  ISIS-FXI Rx .  ...
    (Date:8/4/2015)... Aug. 4, 2015  Armada Health Care ... Medical School,s Clinical Pharmacy Services business unit ... protocols and therapy interventions within the ArmadaOne ... Specialty medication therapy management is an essential ... optimal patient outcomes are achieved through timely ...
    (Date:8/4/2015)... 2015  Delcath Systems, Inc. (NASDAQ: DCTH ), ... oncology with an emphasis on the treatment of primary ... data from studies in Europe ... CHEMOSAT ® Delivery System (CHEMOSAT) will be presented at ... which will be held in Marseille, France ...
    Breaking Medicine Technology:Isis Reports Financial Results And Highlights For Second Quarter 2015 2Isis Reports Financial Results And Highlights For Second Quarter 2015 3Isis Reports Financial Results And Highlights For Second Quarter 2015 4Isis Reports Financial Results And Highlights For Second Quarter 2015 5Isis Reports Financial Results And Highlights For Second Quarter 2015 6Isis Reports Financial Results And Highlights For Second Quarter 2015 7Isis Reports Financial Results And Highlights For Second Quarter 2015 8Isis Reports Financial Results And Highlights For Second Quarter 2015 9Isis Reports Financial Results And Highlights For Second Quarter 2015 10Isis Reports Financial Results And Highlights For Second Quarter 2015 11Isis Reports Financial Results And Highlights For Second Quarter 2015 12Isis Reports Financial Results And Highlights For Second Quarter 2015 13Isis Reports Financial Results And Highlights For Second Quarter 2015 14Isis Reports Financial Results And Highlights For Second Quarter 2015 15Isis Reports Financial Results And Highlights For Second Quarter 2015 16Armada Health Care collaborates with University of Massachusetts Medical School for ArmadaOne Specialty Pharmacy Platform 2Armada Health Care collaborates with University of Massachusetts Medical School for ArmadaOne Specialty Pharmacy Platform 3Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 2Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 3Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 4